×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
WilmerHale Represents Underwriters in $230.5M Celldex Therapeutics Offering
WilmerHale
WilmerHale represented the underwriters in the $230.5M public offering of common stock by Celldex Therapeutics, Inc.
4 months ago
Biotech Stock Celldex Hits High Point On 'Differentiated' Hives Treatment
Investor's Business Daily
Celldex unveiled promising results from a chronic hives treatment on Monday, and the biotech stock hit its highest point since 2021.
1 month ago
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
Yahoo Finance
While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status...
1 month ago
Celldex laces up next to Big Pharma players as drug reduces severity of chronic hives
Fierce Biotech
Celldex reported that barzolvolimab reduced hives on a common score of urticaria activity by -23.87 from baseline in the 300-mg dose group,...
5 months ago
Leerink Partners Serves as Joint Bookrunner for Celldex Therapeutics' (Nasdaq: CLDX) $200 Million Follow-on Offering
Leerink Partners
More Deal Announcements · Leerink Partners Serves as Lead-Left Bookrunner for Edgewise Therapeutics' (Nasdaq: EWTX) $240 Million Follow-On...
5 months ago
Celldex Drug Flashes Potential to Compete With, Maybe Beat Rival Big Pharma Meds
MedCity News
Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two...
5 months ago
Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma
STAT
Today's biotech news updates include the return of the MASH goldrush, next year's flu shot, and Alnylam's recovery.
1 month ago
Celldex Therapeutics shares surge as lead asset shows promise in skin conditions
MarketWatch
Celldex Therapeutics shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead...
5 months ago
Why Celldex Therapeutics Blasted 13% Higher on Monday
The Motley Fool
Celldex Therapeutics ... The biotech's CSU treatment advanced in the laboratory. Clinical-stage biotech Celldex Therapeutics (CLDX -1.43%) was a...
5 months ago
Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal
Scrip
Incyte will pay $750m to acquire privately held Escient and its first-in-class oral antagonists of Mas-related G protein-coupled receptors X2 and X4.
1 day ago